A phase I clinical trial of replication-competent Ad4-HIVenv and Ad4-HIVmosaic gag vaccines has been initiated in the NIH clinical center in collaboration with NIAID and Dr. Mark Connors as Principal Investigator. The study is evaluating the safety and immunogenicity of the vaccines formulated as enteric coated capsules for oral administration and as a liquid for administration to the upper respiratory tract. This study follows a previous Phase I trial of an Ad4-flu vaccine, tested in the clinical center with Dr. Connors as PI. It's value for the HIV vaccine trial was to provide initial safety and dosage informaiton, allowing jump-starting of the HIV vaccine trial. Data from the Ad4-flu study are now being evaluated. New Ad-recombinants are under development both for future clinical use and for pre-clinical studies in the rhesus macaque model. These include recombinants containing novel envelope inserts intended to generate broad, potent neutralizing antibodies. This work includes assessment of the immunogenicity of the newly constructed recombinant vaccines in appropriate animal models. In addition, Ad vectors with deletion of genes not essential for replication of the virus have been developed and expand the carrying capacity of the vaccine vector. They will be evaluated in future preclinical vaccine studies. Previously, the STEP trial, a phase III clinical trial of a non-replicating Ad5-HIV vaccine showed lack of protective efficacy in people together with a suggestion that infection might have been enhanced in individuals with pre-existing immunity to Ad5. To explore the basis for the possible enhancement in Ad seropositive individuals, a recent study examined effects of repeated administration of replication-competent Ad5 to rhesus macaques. The results revealed a complex pattern of responses, including suppression of innate immune responses and transient activation of CD4 T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011063-08
Application #
9153761
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Musich, Thomas; Jones, Jennifer C; Keele, Brandon F et al. (2017) Flow virometric sorting and analysis of HIV quasispecies from plasma. JCI Insight 2:e90626
Qureshi, Huma; GenescĂ , Meritxell; Fritts, Linda et al. (2014) Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques. PLoS One 9:e106004
Thomas, Michael A; Song, Rui; Demberg, Thorsten et al. (2013) Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS One 8:e76344
Qureshi, Huma; Ma, Zhong-Min; Huang, Ying et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86:2239-50
Patterson, L Jean; Kuate, Seraphin; Daltabuit-Test, Mara et al. (2012) Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 19:629-37
Hidajat, Rachmat; Kuate, Seraphin; Venzon, David et al. (2010) Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine 28:3963-71
Demberg, Thorsten; Robert-Guroff, Marjorie (2009) Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28:20-48
Morgan, Cecilia; Marthas, Marta; Miller, Christopher et al. (2008) The use of nonhuman primate models in HIV vaccine development. PLoS Med 5:e173
Patterson, L Jean; Robert-Guroff, Marjorie (2008) Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 8:1347-63